DENVER--(BUSINESS WIRE)-- Cannabis Science, Inc. (OTCBB: CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to inform that the current progress and success with their numerous self-medicated cancer patients, has lead the Company to immediately begin the Investigational New Drug (IND) application process that will target cancer treatment.
Cannabis Science is currently tracking numerous cancer patients, who are self-medicating with cannabis extracts. The Company has evident success with these patients, which creates support to submit an IND application to the FDA. The prescription pharmaceutical market is the number one target market for Cannabis Science, and with having the appropriate backup for the application process, it is all very promising for the Company and cancer patients worldwide.
Cannabis Science currently has documented images for the first three apparently successful self-medicated cancer patients, and the Company is waiting for more documentation and images associated with other patients. The first patient had basal cell carcinoma (skin cancer) on her face, and after applying the topical cannabis extracts within 10 days it appeared the lesion was gone. Cannabis Science received documentation from her surgeon that she would not need to undergo any surgical procedures and was free of cancer cells. The second patient, who has basal cell carcinoma on their arm, has gotten dramatic results. Their treatment has been completed, and Cannabis Science is just waiting for a full biopsy report from the patient’s physician to inform that they are free of cancer cells. A special case, involves a third patient with severe squamous cell carcinoma on his head. His physician prior to using cannabis extracts had told this patient, that there was nothing more that could be done. Cannabis Science has gotten drastic results, along with photographed documentation of the treatment process. This patient’s treatment is still in progress, but with photographic evidence you can see the effectiveness of the cannabis-based extracts.
You can view the photos and information of these patients on the Cannabis Science website www.cannabisscience.com, click the button “Breaking News” and you will find the associated news releases of each patient. You can also view each different patient’s documentation and images by clicking the buttons, “View Images of 1st Self-Medicated Patient & The Apparent Success”, “View Images of 2nd Self-Medicated Patient & The Apparent Success”, and “View Images of 3rd Self-Medicated Patient & His Apparent Success”.
Cannabis Science is in an excellent position to begin the FDA process for prescription cancer medications. Cannabis Science is seeing even more success with other self-medicated cancer patients, and will get updated reports on them as well. All of the positive outcomes from the patients create a suitable foundation to enter the FDA market of prescription drugs.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT:
Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO
[email protected]
www.cannabisscience.com
or
Robert Kane, 1-561-234-6929
Investor Relations Management
[email protected]
[email protected]
www.cannabisscience.com
KEYWORDS: United States North America Colorado
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Oncology Pharmaceutical Research Science
MEDIA: